Zealand Pharma
Update in progressZEAL.CO (Copenhagen)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Zealand Pharma A/S is a biotechnology company focused on discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. Its portfolio targets gastrointestinal and metabolic diseases and other unmet medical needs. It develops Zegalogue for severe hypoglycemia and Dasiglucagon bi-hormone artificial pancreas systems. It is advancing glepaglutide (GLP-2 analog) in Phase III for short bowel syndrome. Founded in 1997, based in Søborg, Denmark.
Company score
- Sentiment
- 0.32
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.11
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.18
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketCopenhagen (CPH)
- LocationDenmark
- CEOMr. Adam Sinding Steensberg M.D.
- Founded1997
- Employees578
- Websitewww.zealandpharma.com
Identifiers
- ISINDK0060257814